Newly developed strategies for improving sensitivity to radiation by targeting signal pathways in cancer therapy

Cancer Science

Volumn 104, Issue 11, 2013, Pages 1401-1410

  Ding, Miao ^a   Zhang, Erlong ^b   He, Rong ^a   Wang, Xingyong ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

^b THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; JANUS KINASE; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN P53; STAT PROTEIN; TUMOR NECROSIS FACTOR ALPHA; WNT PROTEIN;

APOPTOSIS; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; DNA DAMAGE; HUMAN; IONIZING RADIATION; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL; RADIOSENSITIVITY; REVIEW; SIGNAL TRANSDUCTION; TREATMENT RESPONSE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; DRUG SYNERGISM; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS; SIGNAL TRANSDUCTION;

EID: 84886772388     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12252     Document Type: Review

References (63)

1. Yorke E, Gelblum D, Ford E. Patient safety in external beam radiation therapy. Am J Roentgenol 2011; 196: 768-72.
2. Milosevic MF. Hypoxia, anerobic metabolism, and interstitial hypertension. In: Siemann DW, ed. Tumor Microenvironment, 1st edn. Chichester: John Wiley & Sons Ltd, 2010; 183-205.
3. Wachsberger P, Burd R, Dicker AP. Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction. Clin Cancer Res 2003; 9: 1957-71.
4. Kasten-Pisula U, Menegakis A, Brammer I et al. The extreme radiosensitivity of the squamous cell carcinoma SKX is due to a defect in double-strand break repair. Radiother Oncol 2009; 90: 257-64.
5. Zhivotovsky B, Joseph B, Orrenius S. Tumor radiosensitivity and apoptosis. Exp Cell Res 1999; 248: 10-7.
6. Nielsen KV, Müller S, Møller S et al. Aberrations of ERBB2 and TOP2A genes in breast cancer. Mol Oncol 2010; 4: 161-8.
7. Toffalini F, Demoulin JB. New insights into the mechanisms of hematopoietic cell transformation by activated receptor tyrosine kinases. Blood 2010; 116: 2429-37.
8. Squatrito M, Holland EC. DNA damage response and growth factor signaling pathways in gliomagenesis and therapeutic resistance. Cancer Res 2011; 71: 5945-9.
9. Wong KK, Engelman JA, Cantley LC. Targeting the PI3K signaling pathway in cancer. Curr Opin Genet Dev 2010; 20: 87-90.
10. Wagner EF, Nebreda AR. Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer 2009; 9: 537-49.
11. Kim BH, Yi CH, Guo Q et al. A small-molecule compound identified through a cell-based screening inhibits JAK/STAT pathway signaling in human cancer cells. Mol Cancer Ther 2008; 7: 2672-80.
12. Sato N, Yamabuki T, Takano A et al. Wnt inhibitor Dickkopf-1 as a target for passive cancer immunotherapy. Cancer Res 2010; 70: 5326-36.
13. Baud V, Karin M. Is NF-[kappa]B a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov 2009; 8: 33-40.
14. Galina S. Therapeutic targeting of p53 by small molecules. Semi Cancer Biol 2010; 20: 46-56.
15. Zhu Y, Hu J, Hu Y et al. Targeting DNA repair pathways: a novel approach to reduce cancer therapeutic resistance. Cancer Treat Rev 2009; 35: 590-6.
16. Valerie K, Yacoub A, Hagan MP et al. Radiation-induced cell signaling: inside-out and outside-in. Mol Cancer Ther 2007; 6: 789-801.
17. Dent P, Yacoub A, Contessa J et al. Stress and radiation-induced activation of multiple intracellular signaling pathways. Radiat Res 2003a; 159: 283-300.
18. Viloria-Petit A, Crombet T, Jothy S et al. Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy. Cancer Res 2001a; 61: 2413-9.
19. Shiojima I, Walsh K. Role of Akt signaling in vascular homeostasis and angiogenesis. Circ Res 2002; 90: 1243-50.
20. Jeong SJ, Pise-Masison CA, Radonovich MF et al. Activated AKT regulates NF-[kappa]B activation, p53 inhibition and cell survival in HTLV-1-transformed cells. Oncogene 2005; 24: 6719-28.
21. Soderlund K, Perez-Tenorio G, Stal O. Activation of the phosphatidylinositol 3-kinase/Akt pathway prevents radiation-induced apoptosis in breast cancer cells. Int J Oncol 2005; 26: 25-32.
22. Nakamura JL, Karlsson A, Arvold ND et al. PKB/Akt mediates radiosensitization by the signaling inhibitor LY294002 in human malignant gliomas. J Neurooncol 2005; 71: 215-22.
23. Shinohara ET, Cao C, Niermann K et al. Enhanced radiation damage of tumor vasculature by mTOR inhibitors. Oncogene 2005; 24: 5414-22.
24. Gera JF, Mellinghoff IK, Shi Y et al. AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating Cyclin D1 and c-myc expression. J Biol Chem 2004; 279: 2737-46.
25. Gupta AK, Bakanauskas VJ, Cerniglia GJ et al. The Ras radiation resistance pathway. Cancer Res 2001; 61: 4278-82.
26. Khazak V, Astsaturov I, Serebriiskii IG, Golemis EA. Selective Raf inhibition in cancer therapy. Expert Opin Ther Targets 2007; 11: 1587-609.
27. Jones HA, Hahn SM, Bernhard E, McKenna WG. Ras inhibitors and radiation therapy. Semin Radiat Oncol 2001; 11: 328-37.
28. Michael PD, Ross F, Peter MF. Small-molecule inhibitors of MDM2 as new anticancer therapeutics. Semin Cancer Biol 2010; 20: 10-8.
29. Vassilev LT. MDM2 inhibitors for cancer therapy. Trends Mol Med 2007; 13: 23-31.
30. Chinnaiyan P, Allen GW, Harari PM. Radiation and new molecular agents, Part II: targeting HDAC, HSP90, IGF-1R, PI3K, and Ras. Semin Radiat Oncol 2006; 16: 59-64.
31. Fremin C, Meloche S. From basic research to clinical development of MEK1/2 inhibitors for cancer therapy. J Hematol Oncol 2010; 3: 1-11.
32. Dent P, Yacoub A, Fisher PB, Hagan MP, Grant S. MAPK pathways in radiation responses. Oncogene 2003b; 22: 5885-96.
33. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 2009; 9: 798-809.
34. Huang Z, Cheng L, Guryanova O, Wu Q, Bao S. Cancer stem cells in glioblastoma-molecular signaling and therapeutic targeting. Protein Cell 2010; 1: 638-55.
35. Yang YP, Chang YL, Huang PI et al. Resveratrol suppresses tumorigenicity and enhances radiosensitivity in primary glioblastoma tumor initiating cells by inhibiting the STAT3 axis. J Cell Physiol 2012; 227: 976-93.
36. Bonner JA, Trummell HQ, Willey CD, Plants BA, Raisch KP. Inhibition of STAT3 results in radiosensitization of human squamous cell carcinoma. Radiother Oncol 2009; 92: 339-44.
37. Skvortsova I, Skvortsov S, Stasyk T et al. Intracellular signaling pathways regulating radioresistance of human prostate carcinoma cells. Proteomics 2008; 8: 4521-33.
38. Kim KW, Mutter RW, Cao C et al. Inhibition of signal transducer and activator of transcription 3 activity results in down-regulation of Survivin following irradiation. Mol Cancer Ther 2006; 5: 2659-65.
39. Hui Z, Tretiakova M, Zhang Z et al. Radiosensitization by inhibiting STAT1 in renal cell carcinoma. Int J Radiat Oncol 2009; 73: 288-95.
40. Deorukhkar A, Krishnan S, Sethi G, Aggarwal BB. Back to basics: how natural products can provide the basis for new therapeutics. Expert Opin Investig Drugs 2007; 16: 1753-73.
41. Dorai T, Aggarwal BB. Role of chemopreventive agents in cancer therapy. Cancer Lett 2004; 215: 129-40.
42. Kim Y, Kim KH, Lee J et al. Wnt activation is implicated in glioblastoma radioresistance. Lab Invest 2012; 92: 466-73.
43. Kendziorra E, Ahlborn K, Spitzner M et al. Silencing of the Wnt transcription factor TCF4 sensitizes colorectal cancer cells to (chemo-) radiotherapy. Carcinogenesis 2011; 32: 1824-31.
44. Takahashi-Yanaga F, Kahn M. Targeting Wnt signaling: can we safely eradicate cancer stem cells? Clin Cancer Res 2010; 16: 3153-62.
45. Idris AI, Libouban H, Nyangoga H, Landao-Bassonga E, Chappard D, Ralston SH. Pharmacologic inhibitors of IκB kinase suppress growth and migration of mammary carcinosarcoma cells in vitro and prevent osteolytic bone metastasis in vivo. Mol Cancer Ther 2009; 8: 2339-47.
46. Pajonk F, Pajonk K, McBride WH. Inhibition of NF-κB, clonogenicity, and radiosensitivity of human cancer cells. J Natl Cancer Inst 1999; 91: 1956-60.
47. Deorukhkar A, Krishnan S. Targeting inflammatory pathways for tumor radiosensitization. Biochem Pharmacol 2010; 80: 1904-14.
48. Mendonca MS, Chin-Sinex H, Gomez-Millan J et al. Parthenolide sensitizes cells to X-ray-induced cell killing through inhibition of NF-κB and split-dose repair. Radiat Res 2007; 168: 689-97.
49. Sun Y, Clair DK, Fang F et al. The radiosensitization effect of parthenolide in prostate cancer cells is mediated by nuclear factor-κB inhibition and enhanced by the presence of PTEN. Mol Cancer Ther 2007; 6: 2477-86.
50. Magné N, Toillon RA, Bottero V et al. NF-κB modulation and ionizing radiation: mechanisms and future directions for cancer treatment. Cancer Lett 2006; 231: 158-68.
51. Russo SM, Tepper JE, Baldwin AS Jr et al. Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-κB. Int J Radiat Oncol 2001; 50: 183-93.
52. Kirsch DG, Kastan MB. Tumor-suppressor p53: implications for tumor development and prognosis. J Clin Oncol 1998; 16: 3158-68.
53. Vassilev LT. p53 activation by small molecules: application in oncology. J Med Chem 2005; 48: 4491-9.
54. Nielsen LL, Maneval DC. P53 tumor suppressor gene therapy for cancer. Cancer Gene Ther 1998; 5: 52-63.
55. Cohen SJ, Cohen RB, Meropol NJ. Meropol targeting signal transduction pathways in colorectal cancer-more than skin deep. J Clin Oncol 2005; 23: 5374-85.
56. Chung KY, Shia J, Kemeny NE et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005; 23: 1803-10.
57. Lenz H, Mayer R, Gold P et al. Activity of cetuximab in patients with colorectal cancer refractory to both irinotecan and oxaliplatin. Proc Am Soc Clin Oncol 2004; 22: 247s.
58. Zhang E, Zhang C, Su Y, Cheng T, Shi C. Newly developed strategies for multifunctional mitochondria-targeted agents in cancer therapy. Drug Discov Today 2011; 16: 140-6.
59. Cappuzzo1 F, Finocchiaro G, Rossi E et al. EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients. Ann Oncol 2008; 19: 717-23.
60. Viloria-Petit A, Crombet T, Jothy S et al. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo. Cancer Res 2001b; 61: 5090-101.
61. Weickhardt AJ, Tebbutt NC, Mariadason JM. Strategies for overcoming inherent and acquired resistance to EGFR inhibitors by targeting downstream effectors in the Ras/PI3K pathway. Curr Cancer Drug Targets 2010; 10: 824-33.
62. Roti Roti JL, Vander Waal RP, Laszlo A. Thermal modulation of radiation-induced DNA damage responses. Curr Cancer Res 2011; 2: 227-49.
63. Wardman P, Rothkamm K, Folkes LK, Woodcock M, Johnston PJ. Radiosensitization by nitric oxide at low radiation doses. Radiat Res 2007; 167: 475-84.